Target intelligence / Profile preview

Prion protein mRNA (PRNP mRNA)

Target
PRNP mRNA
Molecular classification
Other
01

Overview

Prion protein mRNA (encoded by the PRNP gene in humans and Prnp in mice) is the messenger RNA template responsible for the translation of cellular prion protein (PrPC). In prion diseases—such as Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), and Gerstmann-Straussler-Scheinker (GSS) syndrome—the normal PrPC protein undergoes a conformational transition into a pathogenic, misfolded, and infectious form known as PrPSc. Because PrPC is the essential substrate required for prion replication and propagation, reducing its expression is a highly validated therapeutic strategy. Therapeutic modalities targeting PRNP mRNA include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). These drugs, such as ION717 and ALN-6457, bind to PRNP mRNA to trigger its degradation via RNase H1 or the RNA-induced silencing complex (RISC), respectively, thereby lowering PrPC levels in the brain and halting the progression of neurodegeneration.

Other names
Prnp mRNAPrion protein messenger RNAPRNP transcriptPrnp transcriptMutant PRNP mRNAMutant Prnp mRNAPRNP mRNA encoding PrP
02

Mechanism of action

Antisense oligonucleotides (such as ION717) bind to the complementary PRNP mRNA sequence and trigger RNase H1-mediated degradation of the transcript. Small interfering RNAs (such as ALN-6457 and PrP-siRNA) utilize the RNA-induced silencing complex (RISC) to cleave the PRNP mRNA. Both mechanisms result in the knockdown of PRNP mRNA, thereby reducing the translation and expression of cellular prion protein (PrPC) and preventing its conversion into the pathogenic, misfolded prion protein (PrPSc).

03

Biological functions

Other
04

Disease associations

Neurodegenerative diseaseOther
05

Safety considerations

Potential neurotoxicity or off-target effects of gene-silencing agents in the central nervous systemRisks associated with intrathecal administration (lumbar puncture), such as headache, infection, or bleedingTheoretical consequences of long-term, profound reduction of cellular prion protein (PrPC), although genetic knockouts in animals and humans with heterozygous loss-of-function mutations suggest it is generally well-tolerated
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Cerebrospinal fluid (CSF) prion protein (PrP) levelsPlasma neurofilament light chain (NfL) levelsCSF RT-QuIC (Real-Time Quaking-Induced Conversion) seeding activityPRNP genetic testing

Beyond the preview

Go deeper on Prion protein mRNA (PRNP mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prion protein mRNA (PRNP mRNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call